This website uses cookies

Read our Privacy policy and Terms of use for more information.

All the top Biotech & Pharma news in one daily newsletter.

Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

✅ The Good News ✅

THE GOOD
Business Development & Partnerships

IQVIA and Veeva end legal dispute, form clinical and commercial partnerships allowing cross-platform data integration
Partnership agreement, data integration, clinical development, commercial collaboration, technology services - Read more

Jazz Pharmaceuticals and Saniona partner on epilepsy drug SAN2355, selective Kv7.2/Kv7.3 potassium channel activator ; $42.5M upfront, up to $992.5M in milestones
Licensing deal, neurological, small molecule, milestone payments, epilepsy, R&D - Read more

Ginkgo Bioworks, Inductive Bio, Tangible Scientific partner to streamline AI-driven drug discovery through integrated workflow platform
Research collaboration, AI/ML, drug discovery, pharmaceutical, R&D - Read more

PRESENTED BY PROMOVEO HEALTH
Contract Sales Reps. Half the Budget. Double the Impact.

Stretching your commercial budget?

Get two flex-time reps for the price of one full-time with Promoveo Health.

We build agile field teams that scale up or down based on your brand’s needs — fast.

✅ More Good News ✅

THE GOOD
Fundraises

Sana Biotechnology raises $86.3M public offering for engineered cell therapies
Cell therapy, engineered cells, platform technology, preclinical - Read more

Iantrek raises $42M Series C, bio-interventional ophthalmic surgery company launching AlloFlo Uveo
Ophthalmology, medical device, glaucoma, surgical platform - Read more

Somite.ai raises undisclosed strategic investment from AMD Ventures for AI foundation models for stem cells
Cell therapy, AI/ML platform, stem cells, platform technology, platform-enabled - Read more

THE GOOD
Market Reports

Biotech market recovers after Trump policy shocks, Santé Ventures sees "new normal" for private companies
Venture capital, financial, strategic, market volatility - Read more

THE GOOD
Mergers & Acquisitions

LifeNet Health acquires Netherlands' HCM Medical to expand global reach in regenerative biologics manufacturing
Regenerative biologics, tissue engineering, strategic, major transaction, manufacturing - Read more

Xoma Royalty acquires struggling Mural Oncology for $2.035 per share, continues trend of buying "zombie" biotechs for liquidation
Oncology, strategic acquisition, liquidation, financial transaction, biotech restructuring - Read more

THE GOOD
Politics & Policy

AAP contradicts CDC, recommends COVID-19 vaccination for infants and children despite Kennedy-led policy changes
mRNA vaccine, infectious disease, regulatory, policy conflict - Read more

THE GOOD
Product Launches

Iterum launches Orlynvah, first new uncomplicated UTI antibiotic in 25 years, targeting resistant infections
Antibiotic, infectious disease, strategic, regulatory, first-to-market - Read more

THE GOOD
Regulatory

FDA lifts hold on Rocket Pharmaceuticals' gene therapy trial after addressing patient death concerns
Gene therapy, rare heart disease, regulatory, clinical trial, safety - Read more

Kennedy's CDC vaccine committee firing contradicted by study showing conflicts of interest dropped dramatically since 2000
Vaccine policy, infectious disease, regulatory, scientific integrity - Read more

FDA issues draft guidance prioritizing overall survival data for cancer drug approvals
Oncology, regulatory, strategic, competitive - Read more

PRESENTED BY YOU?
Get the attention of 2000+ Biotech & Pharma Professionals 🤩

sign me up 2 chainz GIF by MOST EXPENSIVEST

Gif: mostexpensivest on Giphy

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

❌ The Bad News ❌

THE BAD
Clinical Trials

Celldex halts barzolvolimab development for eosinophilic esophagitis after Ph2 trial shows KIT inhibitor lacks efficacy
Antibody, autoimmune, monoclonal antibody, eosinophilic esophagitis, KIT inhibitor, gastrointestinal disease - Read more

THE BAD
Layoffs

Catalent cuts 350 gene therapy jobs in Maryland following major customer's reduced demand
Gene therapy, rare disease, operational, workforce reduction - Read more

THE BAD
Politics & Policy

HHS staff demand RFK Jr. stop anti-CDC rhetoric following agency shooting
Public health policy, infectious disease, operational, regulatory - Read more

THE BAD
Regulatory

FDA delays Regeneron's Eylea HD decisions due to manufacturing issues at Catalent facility
Monoclonal antibody, ophthalmology, regulatory, manufacturing, operational - Read more

👹 The Ugly News 👹

THE UGLY
Regulatory

Indian drugmakers recall US medications due to carcinogens and foreign matter contamination
Small molecule, cardiovascular, small molecule, respiratory, regulatory, quality control - Read more

HHS under fire as scientists dispute mRNA research interpretations used to justify funding cuts
mRNA vaccine, infectious disease, regulatory, policy shift, scientific controversy - Read more [Paywall]

You’re all caught up on the latest Pharma & Biotech News!

Season 3 Discovery GIF by Paramount+

Sometime I struggle with what to put for these end gifs - or why I have an end gif in the first place. 🤔 | Gif: paramountplus on Giphy

TLDR Biotech wants to hear from you! 📣

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

Thanks for reading! -Anis

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here